Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib.

CONCLUSIONS: This finding highlights the significance of anemia in CML-CP and suggests that patients with anemia at diagnosis should be carefully monitored and might benefit from more potent TKIs if not achieving 3M-EMR. PMID: 28715941 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28715941?dopt=Abstract

Source: Current Medical Research and Opinion - July 21, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research